# Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix

> **NCT06810895** · — · ENROLLING_BY_INVITATION · sponsor: **Ding Ma** · enrollment: 20 (estimated)

## Conditions studied

- Cervix Cancer
- Cadonilimab
- Small Cell Neuroendocrine Carcinoma of the Cervix

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06810895
- **Lead sponsor:** Ding Ma
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-02-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2032-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06810895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06810895, "Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06810895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*